Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02284893 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
461
Enrollment target
20
Study locations

NCT02284893 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 461 participants, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02284893, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
461 participants
Enrollment target
20
Study locations

Study Summary

Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Sitagliptin
  • DRUG Dapagliflozin
  • DRUG Saxagliptin
  • DRUG Placebo matching with Saxagliptin
  • DRUG Placebo matching with Dapagliflozin

Study Locations (20)

California

  • Research Site - Huntington Beach
  • Research Site - Huntington Park
  • Research Site - Lomita
  • Research Site - Los Angeles
  • Research Site - Northridge
  • Research Site - Norwalk
  • Research Site - Paramount
  • Research Site - Sacramento
  • Research Site - Tarzana
  • Research Site - Tustin

Florida

  • Research Site - Coral Gables
  • Research Site - Kissimmee
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Miami

Arizona

  • Research Site - Mesa
  • Research Site - Mesa
  • Research Site - Phoenix

Arkansas

  • Research Site - Little Rock

Colorado

  • Research Site - Golden

Trial Details

FieldValue
Enrollment Target 461 participants
Start Date 2014-09-09
Est. Completion 2016-09-20
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02284893

The ClinicalTrials.gov registry entry for NCT02284893 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (58% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Sitagliptin is the first listed.

NCT02284893 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02284893 about?

NCT02284893 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone". Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.

What is the current status of trial NCT02284893?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2014-09-09. Estimated completion is 2016-09-20.

What conditions does trial NCT02284893 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT02284893?

The interventions under investigation include: Sitagliptin (DRUG), Dapagliflozin (DRUG), Saxagliptin (DRUG), Placebo matching with Saxagliptin (DRUG), Placebo matching with Dapagliflozin (DRUG).

Who is sponsoring clinical trial NCT02284893?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02284893 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.